Verici DX PLC is a diagnostics company focused on improving outcomes for kidney transplant patients through a suite of proprietary tests. Utilizing artificial intelligence-assisted transcriptomic analysis, Verici DX develops RNA signatures that assess immune responses and biological pathways critical for predicting transplant risks, including injury, rejection, and graft failure. The company serves healthcare providers in the kidney transplant sector, primarily in the United States and Europe, addressing unmet needs for personalized diagnostics and tailored immunosuppressive therapies throughout the transplant journey.